

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



**VOLUNTARY ANNOUNCEMENT
IN RELATION TO
(1) THE FRAMEWORK AGREEMENT; AND
(2) POTENTIAL ACQUISITION**

Reference is made to the announcement of China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 20 April 2022 in relation to inside information and resumption of trading of the Company’s shares (the “**Shares**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the voluntary announcement of the Company dated 17 May 2022 (the “**Announcements**”). Unless otherwise stated, capitalised term used herein shall have the same meanings as those defined in the Announcements.

As mentioned in the Announcements, the Company has been in negotiation with independent third party(ies) regarding the potential acquisition of the commercialisation right of certain monoclonal antibody products (the “**Potential Acquisition**”), the potential disposal of certain assets of the Group (the “**Potential Disposal**”), and a potential strategic co-operation to develop new products of the Group (the “**Potential Co-operation**”, together with the Potential Acquisition and the Potential Disposal, the “**Potential Transactions**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company would like to provide updated information to the shareholders and potential investors of the Company in relation to the Potential Acquisition and the Potential Co-operation.

The Company has been in discussion with a clinical-stage biopharmaceutical company incorporated in USA (the “**Licensor**”) and now have finalized the major terms of the Potential Acquisition which includes the entering into of a licensing & collaboration agreement (the “**Licensing & Collaboration Agreement**”), between the Company and the US Licensor pursuant to which the Licensor is to grant an exclusive and perpetual license to Green-Life Technology (Hong Kong) Company Limited, a wholly-owned subsidiary of the Company (the “**Licensee**”) to commercialise certain monoclonal antibody products (the “**Technology**”) in the PRC, Hong Kong, Macau, Taiwan, Singapore, Malaysia and Thailand. The Technology is currently in Phase II of clinical trial and has been developed by the Licensor for the treatment of various diseases. One of the conditions precedent of the Licensing & Collaboration Agreement will be the entering into of consultancy agreements between the Company, the Licensee and the consultants, pursuant to which the Company shall allot and issue new Shares to the consultants as consideration for the provision of consultancy services on commercializing certain monoclonal antibody products (the “**Consultancy Agreements**”). The consultants will be the leading the research and development of the Technology and will be leading the submission of the clinical application of the Technology with the relevant regulatory authorities. The parties are currently finalising the details of the Licensing & Collaboration Agreement and the Consultancy Agreements.

As mentioned in the Announcements, on 29 April 2022, the Company entered into the Framework Agreement with the Municipal Government in relation to the Potential Cooperation, pursuant to which, among others, the parties shall set up a joint venture company, an integrated biotechnology and pharmaceutical company specialised in research and development, production, sales and services, which is expected to be a subsidiary of the Company (the “**JV Co**”), subject to the terms and conditions of a definitive joint venture agreement. The parties are currently finalising the detailed terms of the joint venture agreement.

As at the date of this announcement, no definitive agreement has been entered into by the Group regarding the Potential Acquisition, the Potential Disposal and set up of the JV Co. Should the Potential Acquisition, the Potential Disposal and set up of the JV Co materialise, they may constitute notifiable transactions under Chapter 14 of the Listing Rules. The Company will make further announcements in relation to the Potential Acquisition, the Potential Disposal and set up of the JV Co in compliance with the Listing Rules, together with the details of the Framework Agreement, as and when appropriate.

Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the Shares.

By order of the Board
China NT Pharma Group Company Limited
NG Tit
Chairman

Hong Kong, 14 June 2022

As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Director is Dr. Qian Wei; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Pan Fei and Dr. Zhao Yubiao.